Long‐term effects upon rituximab treatment of acquired angioedema due to C1‐inhibitor deficiency

Allergy ◽  
2018 ◽  
Vol 74 (4) ◽  
pp. 834-840 ◽  
Author(s):  
Marcel Levi ◽  
Danny Cohn ◽  
Sacha Zeerleder ◽  
Magdalena Dziadzio ◽  
Hilary Longhurst
2011 ◽  
Vol 24 (4) ◽  
pp. 1115-1118 ◽  
Author(s):  
E. Di Leo ◽  
E. Nettis ◽  
V. Montinaro ◽  
G. Calogiuri ◽  
P. Delle Donne ◽  
...  

Author(s):  
Mohammed Olaythah Alraddadi ◽  
Yousef Hussain J. Alharthi ◽  
Rayyan Fahad H. Altemani ◽  
Wejdan Mohammed S. Alshehri ◽  
Amal Nafea J. Alharbi ◽  
...  

AAE-C1-INH (acquired angioedema owing to C1-inhibitor (C1-INH) deficiency) is a dangerous illness that can lead to asphyxiation due to laryngeal edoema. Only around 1% to 2% of angioedema cases are classified as HAE or AAE, with HAE being 10 times more prevalent than AAE. The sole clinical distinction between HAE and AAE is the age at which symptoms appea, AAE-C1-INH is usually diagnosed after 40 years of age. There is no licensed therapy for AAE-C1-INH at this time. AAE-C1-INH attacks are treated with HAE-C1-INH medicines such plasma-derived C1-INH concentrate (pdC1-INH) and the bradykinin B2 receptor antagonist, icatibant. These on-demand medications are thought to be most helpful when provided early in the attack. However, there is a scarcity of published data on the efficacy and safety of AAE-C1-INH therapies.


2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Peter Stepaniuk ◽  
Amin Kanani

Abstract Background Hereditary angioedema (HAE) is an inherited condition manifesting as recurrent angioedema episodes which is caused by deficiency or dysfunction of C1 inhibitor. Although complement dysregulation has historically been shown to be associated with various malignancy and immune disorders, it is currently not known if HAE patients are at an increased risk of developing malignancy or autoimmune conditions. Case presentation We reviewed the charts of 49 HAE patients and identified 6 patients who had a co-existing malignancy diagnosis (two with breast cancer, one with melanoma, one with pancreatic cancer, one with renal cancer and one with cervical dysplasia) and 6 patients who had a diagnosis of a co-existing immune disorder (two with rheumatoid arthritis, two with ulcerative colitis, one with chronic urticaria with hypothyroidism and one with Sjogren’s syndrome). Nearly all malignancy cases occurred in older HAE patients (> 50 years) and malignancy was diagnosed before HAE in 3 of the patients. Conclusions Our case series identified multiple hereditary angioedema (HAE) patients with co-existing malignancy and immune disorders. Based on these findings, we would advocate that physicians managing HAE patients should maintain a high index of suspicion for these conditions and that in patients with angioedema, C1 inhibitor deficiency and malignancy, a diagnosis of HAE should still be considered in addition to acquired angioedema (AAE).


2017 ◽  
Vol 139 (2) ◽  
pp. AB232
Author(s):  
Mauro Cancian ◽  
Andrea Zanichelli ◽  
Francesco Arcoleo ◽  
Maria Bova ◽  
Riccardo Senter ◽  
...  

2006 ◽  
Vol 119 (8) ◽  
pp. e3-e5 ◽  
Author(s):  
Marcel Levi ◽  
C. Erik Hack ◽  
Marinus H. van Oers

Sign in / Sign up

Export Citation Format

Share Document